David A. Reardon, MD Dana-Farber Cancer Institute discusses What is the rationale in combining these agents together? – INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results.
INO-5401 and INO-9012 in combination with cemiplimab REGN2810 – What is the rationale in combining these agents together? – David A. Reardon, MD Dana-Farber Cancer Institute @DanaFarber #…
By Editor